LC-MS Study Shows Reliable way to Measure Leukemia Markers

A study led by cancer researchers at Ohio State University's Comprehensive Cancer Center's Experimental Therapeutics Program.has validated a method for reliably measuring variations in certain proteins that may make good biomarkers in chronic leukemia patients.

A study led by cancer researchers at Ohio State University's Comprehensive Cancer Center's Experimental Therapeutics Program.has validated a method for reliably measuring variations in certain proteins that may make good biomarkers in chronic leukemia patients. The study shows that LC-MS can measure variations in histones. The technology accurately detected differences in the composition of histones in chronic lymphocytic leukemia (CLL) cells compared with their healthy counterparts- B lymphocytes. These variations are a promising molecular biomarker that might improve the diagnosis and gauge response to therapy in CLL patients.